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Plasma Angiotensin II and the 
Antihypertensive Action of Angiotensin-
Converting Enzyme Inhibition 
/. Nussberger, B. Waeber, and H. R. Brunner 
The measurement of immunoreactive "angiotensin 
II" in plasma cannot provide an accurate reflection 
of the efficacy of angiotensin-converting enzyme 
(ACE) inhibition because different angiotensin 
fragments interfere in all radioimmunoassays 
available so far. More complex methods are neces-
sary in order to measure specifically angiotensin-
(l-8)octapeptide. With such methodology it can be 
shown that no tolerance develops to the angiotensin 
II-reducing effect of ACE inhibitors after prolonged 
administration. Marked reduction of angiotensin II 
levels can be shown even in patients with primary 
aldosteronism. At peak blockade, the level of 
plasma angiotensin II is still related to circulating 
active renin and angiotensin I. Accordingly, be-
cause ACE inhibitors raise circulating angiotensin I 
in a dose-dependent fashion, this should be taken 
into account when dosing ACE inhibitors. The 
hypothesis that tissue renin-angiotensin systems 
play an important independent role in determining 
vasomotor tone is very interesting. However, any 
discussion on whether tissue or plasma renin 
determines the pharmacological effect of ACE in-
hibitors should be based on the simultaneous 
measurement of true angiotensin II in tissue and 
plasma under steady-state conditions. Am J Hyper-
tens 1989;2:286-293 
K E Y W O R D S : Angiotensin II/angiotensin I ratio, 
dosing ACE inhibitors, primary aldosteronism, 
tissue renin angiotensin system. 
In the enzymatic cascade of the renin-angiotensin system, angiotensin II clearly is the main effector hormone whereas the enzymatic activity of renin represents the rate-limiting step in the generation of 
angiotensin II. Because it has been well recognized that 
the measurement of angiotensin II in plasma presents 
many problems, the measurement of plasma renin ac-
tivity, ie, in vitro angiotensin I generation under stan-
dardized conditions, has become the substitute for the 
measurement of angiotensin II. All evidence available 
suggested that there is indeed a very good correlation 
between circulating angiotensin II and the measured 
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plasma renin activity. The measurement of plasma renin 
activity has indeed turned out to be extremely useful to 
assess the degree of activation of the renin-angiotensin 
system under physiological and pathophysiological 
conditions. 
This situation was completely changed when con-
verting-enzyme inhibitors became available for experi-
mental and clinical research. 1" 4 These agents are de-
signed to dissociate the generation of angiotensin II 
from renin activity. They markedly reduce angiotensin 
II generation while actually stimulating renin secretion. 
As a consequence, the measurement of plasma renin 
activity is no substitute any more for the measurement 
of angiotensin II. True, methods were developed to 
measure the plasma activity of angiotensin-converting 
enzyme (ACE). However, these again measure the in 
vitro activity under standardized conditions and the re-
sults do not necessarily parallel the in vivo activity. Fur-
thermore, it became evident that in the organism the 
bulk of the conversion of angiotensin I to angiotensin II 
is carried out by converting enzyme located on the vas­
cular endothelial cells. Therefore, does converting-en­
zyme activity measured in plasma truly reflect global in 
vivo conversion? Inevitably, in order to directly assess 
the effect of ACE inhibitors, plasma angiotensin II 
rather than plasma ACE or renin activity has to be mea­
sured, and there is no real substitute for it. The need for 
this measurement is further emphasized by the devel­
opment of a new generation of agents designed to in­
hibit the action of the enzyme renin itself. 5 , 6 These com­
pounds also reduce the generation of angiotensin II 
whereas plasma ACE activity is not altered and renin 
secretion is actually enhanced. 
The purpose of the following presentation is to dis­
cuss the fate of plasma angiotensin II during acute and 
long-term ACE inhibition, its relationship to circulating 
angiotensin I, and the problems encountered when 
measuring plasma angiotensin II. Because it is claimed 
with growing insistence that mainly tissue renin systems 
completely independent of plasma renin and angioten­
sin determine blood pressure, it seems more than ever 
imperative to study the fate of plasma angiotensin II 
carefully to establish a solid base from which to investi­
gate tissue systems. Only based on a precise under­
standing of the behavior of plasma angiotensin II can 
true dissociations of tissue angiotensin II from plasma 
angiotensin II under steady-state conditions be identi­
fied, and this turns out to represent a formidable meth­
odological task. 
IMMUNOREACTIVE "ANGIOTENSIN II" 
DURING ACE INHIBITION: RELATIONSHIP 
TO RENIN AND ANGIOTENSIN I 
In 1981, once the efficacy of the converting-enzyme 
inhibitor enalapril had been established in normal vol­
unteers, 7 this same compound was administered to 19 
hypertensive patients.8 When evaluating the data ob­
tained from the measurement of imunoreactive "angio­
tensin Π" (ir-ANG II) and of plasma renin activity, a 
very interesting and at that time surprising relationship 
was observed. As one would have expected, before the 
administration of enalapril, plasma ir-ANG II levels of 
the nine patients in whom they were measured corre­
lated very well with the corresponding plasma renin 
activity. These results are illustrated in panel A of Figure 
1. In all four panels, this initial ir-ANG II to plasma renin 
activity relationship is depicted as a solid line. Also 
shown in all panels are two parallel dotted lines that 
represent the relationship (regression line ± 1 SD from 
regression) that was observed previously in normal vol­
unteers four and ten hours after administration of 10 mg 
of enalapril or lisinopril.7 Results obtained four hours 
after administration of 10 or 20 mg of enalapril are illus­
trated in panel B. They fall within the range determined 
in the normal volunteers. Interestingly, even at peak 
ACE inhibition, there is still a clear and statistically sig­
nificant correlation between plasma ir-ANG II and 
plasma renin activity, though the slope of this correla­
tion is considerably shifted compared to that observed 
before the administration of enalapril (slope of dotted 
versus slope of solid line). In panel C, data obtained 12 
to 16 hours after 10 or 20 mg of enalapril are depicted. 
Plasma ir-ANG II levels tended to increase in some of 
the patients (values above the dotted lines), suggesting a 
tendency for the blockade to wear off. In panel D, 
plasma ir-ANG II24 hours after enalapril have returned 
to baseline. However, the normal relationship deter­
mined before blockade is still not reached, because the 
return to baseline of ir-ANG II levels has occurred in the 
face of a still markedly elevated plasma renin activity. 
Already several years back, these data suggested that 
even during peak ACE inhibition, ir-ANG II levels are 
still under the influence of the concomitant plasma 
renin activity and thus angiotensin I. Two important 
conclusions from these observations could be drawn: 
first, converting-enzyme inhibition was not complete, 
even at peak effect, and second, therefore the concomi­
tant renin and angiotensin I levels prevailing during 
ACE inhibition might be of greater importance than 
generally appreciated. 
In a more recent study, using a new ACE inhibitor, 
trandolapril (Roussel Uclaf, Paris, France), similar ob­
servations were made (unpublished data). This com­
pound was administered to groups of normal volunteers 
at three dose levels, ie, 0.5, 2, or 8 mg po qd for ten days. 
On day 1 and day 10, the various components of the 
renin-angiotensin system were determined in the 
plasma before and 2, 4, and 6 hours post-drug. As well 
on day 1 as on day 10, the measurement of plasma ACE 
activity clearly reflected the dose of drug administered, 
because a clearly dose-dependent ACE inhibition was 
observed. That this measurement reflected global ACE 
inhibition was confirmed by the ratio of plasma ir-ANG 
II / angiotensin I that was equally reduced in dose-de­
pendent fashion. However, on day 1, but even more so 
on day 10, the increasing doses of the ACE inhibitor 
induced a marked rise in angiotensin I levels that again 
was clearly dose-dependent. Thus, the progressive ACE 
blockade obtained with increasing doses of the ACE 
inhibitor induced dose-dependent increases in plasma 
angiotensin I. Plasma ir-ANG II levels were significantly 
reduced with the 0.5 mg dose, but more so on day 10 
than on day 1. In contrast, with the 8 mg dose ir-ANG II 
levels were also reduced, but they tended to be higher 
on day 10 than on day 1. As a consequence, plasma 
levels of ir-ANG II on day 10 at peak effect of the drug 
were actually the same with the 0.5 mg as with the 8 mg 
dose. Thus, the concomitant angiotensin I levels again 
seemed to determine the plasma ir-ANG II levels. Rais­
ing the dose of the ACE inhibitor did not produce any 
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F I G U R E 1. Relationship between immunoreactive angiotensin II and renin activity in plasma of hypertensive patients before 
converting-enzyme inhibition (panel A) and 4 hours (panel B), 12 to 16 hours (panel C), and 24 hours (panel D) after enalapril intake (10 
or 20 mg). In all panels, the regression of panel A is represented by the solid line. The ANG II/PRA-relationship of normal volunteers 
during peak ACE inhibition (4 and 10 hours after 10 mg enalapril) is represented by the area between the dotted lines (regression ± 
1 SD). Recovering from ACE inhibition, ir-ANG II reaches pretreatment levels when PRA is still markedly increased. Reproduced from 
Biollaz et al with permission.8 
additional gain, even though it did enhance the degree 
of ACE inhibition, because this was offset by the com-
pensatory rise in renin secretion and consequently an-
giotensin I levels. 
These observations lead to several comments. As-
suming that ACE inhibitors reduce blood pressure by 
reducing plasma angiotensin II, what is the optimal dose 
of an ACE inhibitor? In our mind, it has always been 
doubtful that for any ACE inhibitor increasing the dose 
that provides biochemical maximal ACE-inhibition 
once a day results in a net therapeutic gain. For the first 
time, our observation suggesting that increasing doses 
do not produce lower and lower plasma angiotensin II 
levels may provide an explanation for the lack of thera-
peutic benefit derived from dose increases. Further-
more, these observations also let the simultaneous ad-
ministration of an ACE inhibitor with a ^-adrenoceptor 
blocking agent appear in a new light. It is generally 
thought that the association of a /^-blocker with an ACE 
inhibitor is not very useful, but unquestionably in some 
individual patients a net additive antihypertensive ef-
fect can be obtained by associating these two types of 
compounds. Is it possible that this association is particu-
larly beneficial in those patients who raise their plasma 
renin activity and angiotensin I levels more than the 
average hypertensive patient? 
As interesting as these results may appear, they were 
obtained measuring ir-ANG II. The specificity of these 
angiotensin II to angiotensin I relationships still re-
mained to be established, and therefore better method-
ology to measure true angiotensin II was clearly needed. 
PLASMA ANGIOTENSIN II VERSUS BLOOD 
PRESSURE 
Already in the late 1970s when captopril was still used 
at excessive doses, a clear dissociation in time between 
ACE inhibition and blood pressure reduction was ob-
served.9 Thus, in patients treated for several weeks with 
captopril, 12 hours after the last dose of 200 mg, no ACE 
inhibition could be demonstrated any more, whereas 
blood pressure was still reduced. 
The same phenomenon has also been observed with 
enalapril. If it is administered once a day, it clearly con-
trols blood pressure throughout 24 hours. However, this 
continuous blood pressure control occurs despite a re-
turn to baseline of plasma ir-ANG II before the subse­
quent administration of enalapril. 8 , 1 0 
Based on this dissociation between ACE inhibition 
and reduction of angiotensin II levels on the one hand 
and blood pressure decrease on the other, it has been 
claimed that ACE inhibitors do reduce blood pressure 
by an angiotensin II independent mechanism, for in­
stance via accumulation of bradykinin 1 1 or an increase 
in vasodilating prostaglandins.1 2 An alternative expla­
nation has been that ACE inhibitors reduce blood pres­
sure by inhibiting the conversion of angiotensin I to 
angiotensin II in the vascular wall rather than in plasma, 
because ACE inhibition may last longer in t issues . 1 3 - 1 5 
Whereas this represents a fascinating concept, it would 
still have to be explained why the reappearing angio­
tensin II in plasma cannot reach the vascular angioten­
sin II receptor, when it is known that angiotensin I and II 
diffuse easily from the plasma into the tissues and vice 
versa. Most important however, when appreciating this 
dissociation one must keep in mind the behavior of 
many of the other antihypertensive drugs. Thus, it is 
well known that there exists no clear relationship be­
tween the plasma half-life of any antihypertensive drug 
and the duration of its antihypertensive action. A phe­
nomenon that has been recognized a long time ago is the 
dissociation between the plasma levels after discontin­
uation of an antihypertensive drug and the increase in 
blood pressure. Often it takes weeks and months after 
discontinuation of the drug before blood pressure starts 
to rise or reaches the hypertensive levels known to exist 
before initiation of treatment. Accordingly, the dissocia­
tion between the half-life of ACE inhibitors and the 
antihypertensive effect is a phenomenon that is not spe­
cific for these drugs. 
DOES TOLERANCE DEVELOP TO 
LONG-TERM ACE INHIBITION? 
During the first study of enalapril in hypertensive pa­
tients, we noticed that plasma ir-ANG II levels of the 
eight patients treated for six months tended to return to 
baseline levels after initial marked suppression.1 6 This 
of course raised the question, whether tachyphylaxis 
developed to the enzyme inhibitory effect of enalapril. 
However, plasma ir-ANG II levels had been measured 
12 hours after the last dosing and not at peak effect. 
Furthermore, five out of the eight patients also took a 
diuretic in order to normalize their blood pressure. 
In order to clarify this issue of tachyphylaxis, six hy­
pertensive patients continuously treated with enalapril 
for an average of two years were brought to the outpa­
tient department on the morning before taking their 
daily dose of the ACE inhibitor. 1 7 The goal was to do a 
carefully timed study of the components of the renin-
angiotensin system after taking the usual morning dose. 
Plasma renin and ACE activity as well as blood angio­
tensin I and plasma ir-ANG II were measured before 
and 2, 4, and 6 hours after medication. Clearly, even 
after two years of uninterrupted treatment with enala­
pril, plasma ir-ANG II levels fell by approximately 5 0 % 
after taking the converting-enzyme inhibitor. Figure 2 
illustrates the relationship between plasma ir-ANG II 
and blood angiotensin I levels before and 2, 4, and 6 
hours post-drug. Not only did plasma ir-ANG II exhibit 
a substantial fall after enalapril administration, but also 
blood angiotensin I levels increased markedly, thus re­
flecting the characteristic behavior of the renin-angio­
tensin system following ACE inhibition. 
These data demonstrate quite clearly that the en­
zyme-inhibiting effect of enalapril does not wear off 
after an average treatment period of two years and most 
probably not thereafter. The ACE inhibitor, even with 
long-term administration, reduces the generation of ir-
ANG II. This however does not preclude a rise in blood 
pressure, or even a return of blood pressure to the initial 
hypertensive levels. For instance, any sodium retention 
due to a change in renal function, in diet, or a reduction 
in concomitant diuretic therapy can result in what might 
appear as tachyphylaxis. This of course is not a true 
tachyphylaxis, because the weakening of the antihyper­
tensive effect is not related to a reduced pharmacologi­
cal action of the ACE inhibitor, but rather to a change in 
other unrelated factors contributing to blood pressure 
regulation. 
Figure 2 demonstrates one other fact that corresponds 
with the results obtained by all the other investigators 
measuring plasma ir-ANG II: even at peak effect of any 
ACE inhibitor, plasma ir-ANG II never is reduced to 
zero. Similarly, even after total nephrectomy of animals, 
substantial amounts of ir-ANG II keep circulating in the 
plasma. 1 8 It seemed important to investigate whether 
this truly represented angiotensin II or whether these 
remaining levels of immunoreactive "angiotensin Π" 
were due to some measuring artifact. Therefore the 
quantitation of plasma angiotensin II needed to be im­
proved. 
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MEASUREMENT OF TRUE 
ANGIOTENSIN-(l-8)OCTAPEPTIDE 
Circulating in plasma is not only the octapeptide angio-
tensin II, but also the precursor decapeptide angiotensin 
I, its C-terminal nonapeptide, and breakdown frag-
ments consisting of 7, 6 ,5 , and less amino-acids. Angio-
tensin I differs from angiotensin II only by the two 
amino-acids at the C-terminal. On the other hand, the 
breakdown products of angiotensin II have their se-
quence reduced starting from the N-terminal. As a con-
sequence, in order to measure specifically angiotensin II 
by radioimmunoassay alone, antibodies would be 
needed that identify simultaneously the N- and the C-
terminal. 1 9 So far, antisera of such properties have not 
become available in sufficient quantity, and the antisera 
in use are mostly selective for the C-terminal of angio-
tensin II. Accordingly, they differentiate quite readily 
angiotensin II from angiotensin I but exhibit a consider-
able cross-reactivity with the smaller fragments. When 
using such antisera, it is necessary in order to improve 
the specificity of the assay to separate the different an-
giotensins before radioimmunoassay. This separation 
can be achieved by high performance liquid chromatog-
raphy (HPLC). Detection limits of conventional HPLC 
procedures are several orders of magnitude higher than 
the attomoles to be quantitated in plasma angiotensin II 
measurement during ACE inhibition. By combining the 
almost absolute specificity of HPLC with the extreme 
sensitivity of a radioimmunoassay, it has become possi-
ble to measure specifically angiotensin^l-8)octapeptide 
with a limit of detection of 0.1 fmol/mL and an overall 
recovery rate of 80% and more. 2 0 Moreover, this meth-
odology enables the quantitation of the various metabo-
lites of angiotensin II in plasma. It actually turned out 
that one reason for ir-ANG II in plasma not to fall to zero 
after acute converting-enzyme inhibition is the presence 
of cross-reacting angiotensin fragments in plasma. 2 1 
Even after these improvements, an important prob-
lem persisted that finally could be solved. Conventional 
inhibitor cocktails containing EDTA and other pepti-
dase inhibitors do not stop renin activity immediately 
after blood sampling. 2 1 In order to avoid angiotensin 
generation in vitro, Waite 2 2 had introduced several years 
ago the method of whole blood precipitation immedi-
ately after blood drawing in order to measure circulating 
angiotensin I. The same problem prevails when mea-
suring plasma angiotensin II, because particularly after 
ACE inhibition substantial amounts of renin are present 
in plasma that continue to produce enormous amounts 
of angiotensin I in the test tube. These tend to generate 
in vitro ir-ANG II, albeit at a reduced rate due to the 
presence of EDTA and the specific ACE inhibitor. It has 
been shown in vivo and in vitro that angiotensin II can 
be generated during potent ACE inhibition. Adding a 
synthetic renin inhibitor to the sampling tube prevents 
in vitro generation of angiotensin I and II and thus fur-
ther improves the measurement of circulating angioten-
sin II . 2 3 At the same time, whole blood precipitation for 
the measurement of angiotensin I has become obsolete. 
With this markedly improved though somewhat te-
dious methodology, the investigation of the precise role 
of angiotensin II in blood pressure regulation particu-
larly before and during ACE inhibition has become fea-
sible and reproducible. Knowing all the pitfalls possible 
with the measurement of plasma angiotensin II, it is not 
surprising that this measurement has not led so far to the 
unraveling of its role in blood pressure homeostasis. 
Whatever the errors committed in the past, today it 
seems inappropriate to attempt the characterization of 
ACE inhibition and of the role of angiotensin II using 
any second best methodology or even relying solely on 
the measurement of immunoreactive "angiotensin II ." 
TRUE ANGIOTENSIN II DURING ACE 
INHIBITION 
In a pilot study, when ramipril (Hoechst AG, Frankfurt, 
Germany) was administered to normotensive volun-
teers, it reduced ir-ANG II by only 4 6 % . 2 0 In contrast, 
true angiotensin II or angiotensin^l-8)octapeptide fell 
from 5.2 ± 1.2 fmol/mL to undetectable levels 
( < 0 . 4 fmol/mL). Thus, for the first time, it could be 
demonstrated that at least with acute initial administra-
tion of an ACE inhibitor, plasma angiotensin II was 
virtually reduced to zero, as we would have expected 
based on theoretical considerations. 
A similar experiment was carried out, during which 
not only immunoreactive and true angiotensin II were 
measured but also plasma-converting enzyme and renin 
activity as well as blood angiotensin I and plasma aldos-
terone levels. 2 0 The behavior of these different compo-
nents was followed over a period of 24 hours (Figure 3). 
One hour after the administration of ramipril, plasma 
ACE activity was reduced by more than 90%, plasma 
angiotensin-(l-8)octapeptide had fallen from 3.8 ± 1 . 0 
to undetectable levels, whereas immunoreactive "an-
giotensin II" had only decreased by 44%. At this time, 
plasma renin activity and blood angiotensin I levels had 
hardly changed. By four hours post-drug, plasma an-
giotensin-^-8) octapeptide was again detectable and it 
reached by eight hours 1.5 f mol/mL when plasma renin 
activity and angiotensin I levels had increased at least 
five-fold. These results again strongly suggest, but this 
time based on the measurement of true angiotensin II in 
plasma containing EDTA and phenanthroline, that this 
hormone is still under the influence of circulating renin, 
even at the peak effect of an ACE inhibitor. Preliminary 
data of similar experiments but with renin-inhibitor in 
the blood sampling tubes lead to the same conclusion 
and therefore indicate that we are dealing with an in 
vivo phenomenon rather than with an in vitro artifact.2 3 
Plasma angiotensin II and ACE activity were also 
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FIGURE 3. Response of the renin-angio­
tensin-aldosterone system to short-term con­
verting-enzyme inhibition with a single oral 
dose of ramipril (10 or 20 mg) in four normal 
volunteers. ANG-(l-8)octapeptide virtually 
disappeared from plasma whereas levels of 
immunoreactive "angiotensin 11" decreased 
by only 44°/o. Reproduced from Nussberger et 
al with permission.20 
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measured in nine patients treated for at least eight 
months with enalapril. 2 0 Blood samples were drawn on 
EDTA/phenanthroline in the morning before and two 
hours after the administration of enalapril. Plasma-con­
verting enzyme activity fell from 17 ± 5 . 4 to 0.9 ± 
0.3 nmol/mL/h. At the same time, plasma immunore­
active "angiotensin II" fell by a mere 17%, whereas 
plasma angiotensin^l-8)octa peptide decreased from 
2.7 ± 0.9 to 0.9 ± 0.3 fmol/mL (P < .05). These results 
confirmed once more that, probably due to renin stimu­
lation, angiotensin^ l-8)octapeptide remains present in 
plasma of patients treated for a prolonged period of time 
with ACE inhibitors. They also underlined the fact that 
there exists no tachyphylaxis to the converting-enzyme 
inhibitory effect of enalapril and to blockade of angio­
tensin II generation in plasma, despite some claims to 
the contrary. 
One feature of ACE inhibitors has been used repeat­
edly as evidence in favor of an angiotensin II indepen­
dent antihypertensive effect of these agents. Not only 
patients with elevated plasma renin activity, but also 
many with what appear to be "normal" or even low 
renin levels respond to monotherapy by an ACE inhibi­
tor with a decrease in blood pressure. The argument is 
actually based on two lines of thought: a low plasma 
renin activity cannot have any effect on vascular tone 
and, if angiotensin II levels are already low, they cannot 
fall further during ACE inhibition. The contribution of 
angiotensin II to blood pressure regulation is a complex 
question involving changes in receptor availability and 
affinity and interactions with many other pressor and 
depressor systems, and therefore, it cannot be tested 
easily. On the other hand, it seemed appropriate to in­
vestigate whether an ACE inhibitor can reduce circulat­
ing angiotensin II in patients who have extremely low 
levels to start with, ie, in patients with documented pri­
mary aldosteronism. 
EFFECT OF ACE INHIBITION ON 
ANGIOTENSIN II OF PATIENTS WITH 
PRIMARY ALDOSTERONISM 
Figure 4 illustrates the effect of converting-enzyme inhi­
bition on the components of the renin-angiotensin sys­
tem of three patients with primary aldosteronism. The 
shaded areas represent the normal range of the variables 
measured (mean ± 2 SD in supine normal volunteers), 
the lower end of the logarithmic scale represents the 
detection limit, and the heavy lines illustrate the mean 
value of the three patients. The patients came to the 
outpatient facility one hour before starting the study 
Angiotensin II 
pg/ml 
50 
30 Η 
Active Renin 
pg/ml io-
Captopril 25mg i.v. 
Captopril 25 mg i.v. 
3 0 
* 2 
Aldosterone 
pg/ml 
Plasma 
Renin Activity 
ng / ml / h 
FIGURE 4. Response of the plasma 
renin-angiotensin-aldosterone system to 
acute converting-enzyme inhibition in 
three patients with primary aldosteron­
ism. The heavy line represents the mean 
values. Shaded areas represent the nor­
mal range (mean ± 2 SD) obtained in 15 
supine healthy subjects. The lower end of 
the logarithmic scales indicates the de­
tection limit of our methods. Low initial 
angiotensin-(l-8)octapeptide concentra­
tions further decrease after captopril, 
whereas aldosterone levels remain ab­
normally high and renin values ex­
tremely low. 
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and they were installed comfortably in a supine posi­
tion. After blood sampling to establish predrug baseline 
captopril was given as a bolus intravenous injection at a 
dose of 25 mg. Low plasma renin activity and abnor­
mally high plasma aldosterone levels predrug con­
firmed the diagnosis of primary aldosteronism. Follow­
ing the administration of captopril, plasma angiotensin 
II that was low to begin with at 1.80 ± 0.70 fmol/mL 
(mean ± SEM) fell markedly to 0.17 ± 0.09 fmol/mL 
90 minutes after captopril injection. 
These results clearly demonstrate that even in pa­
tients with the lowest possible angiotensin II levels to 
start with, ACE inhibition still substantially reduces cir­
culating angiotensin II. It is therefore certainly inappro­
priate to assume that ACE inhibitors cannot reduce 
plasma angiotensin II in patients with low renin hy­
pertension. Indeed, blood pressure of these patients 
with primary hyperaldosteronism did not fall substan­
tially after the administration of captopril. However, 
response or nonresponse of blood pressure to substan­
tial angiotensin II reduction has nothing to do with the 
inhibitory efficacy of the drug per se but rather with the 
set-point of the pressure-response curve to prevailing 
angiotensin II levels that is known to be highly variable 
from one patient to the other and also within a given 
patient depending on many variables. 
PLASMA ANGIOTENSIN II DURING RENIN 
INHIBITION 
The goal of renin inhibition being the same as that of 
ACE inhibition, ie, reduction of angiotensin II genera­
tion, the measurement of plasma angiotensin II can be 
used just the same way to assess the efficacy and po­
tency of renin inhibitors. This has been done recently, 
administering two renin inhibitors, CGP 385 60A (Ciba-
Geigy, Basel, Switzerland) and A-64662 (Abbott Labo­
ratories, Abbott Park, Illinois) to normal volunteers by 
either 30 minute IV infusion or bolus IV infusion. 2 4 , 2 5 
Both compounds reduced plasma angiotensin^l-8)oc-
tapeptide in a dose-dependent fashion to very low 
levels, comparable to those observed during ACE inhi­
bition. Thus, the measurement of plasma angiotensin II 
makes it possible not only to evaluate the efficacy of any 
new renin inhibitor but also to compare it to that of ACE 
inhibitors. 
CONCLUSIONS 
Because angiotensin II appears to be the only vasoactive 
component of the renin-angiotensin system, any assess­
ment of drugs designed to inhibit this system and 
thereby to reduce vasomotor tone, should be based on 
the accurate measurement of the octapeptide angioten­
sin II. The quantitation of this hormone in plasma has 
presented considerable difficulties but at the present, 
precise methods are available to determine angiotensin 
II in plasma with a high degree of specificity and sensi­
tivity. Using this approach, it can be clearly demon­
strated that ACE inhibitors reduce circulating angioten­
sin II and that no tolerance develops with prolonged use 
of this drug. Expressed differently, even though there 
exists some dissociation in time between the antihyper­
tensive effect and the angiotensin II-reducing action of 
ACE inhibitors, there is little evidence that ACE inhibi­
tors ever lower blood pressure without reducing plasma 
angiotensin II levels at least for a short period during the 
day. It could also be shown that even during peak 
blockade angiotensin II levels are probably still under 
the influence of circulating active renin. Accordingly, 
ACE inhibitors should be used in a way that provides 
maximal angiotensin II reduction in the face of minimal 
increase in active renin. There seems to be little benefit 
in increasing excessively the dose of ACE inhibitors, 
because circulating angiotensin II levels may not be fur­
ther reduced. On the other hand, even in patients with 
very low plasma angiotensin II, such as patients with 
primary aldosteronism, plasma angiotensin II can still 
be shown to be markedly reduced by ACE inhibition. 
Accordingly, there is little doubt today that acute as well 
as long-term administration of an ACE inhibitor at ade­
quate doses markedly reduces angiotensin II in plasma. 
Whether this fall in circulating angiotensin II induces 
any change in blood pressure depends on the interaction 
of several independent variables prevailing in a given 
patient that determine the set-point of the pressure-re­
sponse to angiotensin II. 
In these clinical studies, angiotensin II has only been 
measured in plasma. The determination of angiotensin 
II in tissue will present even greater methodological dif­
ficulties and will probably be of little practical use in 
clinical medicine. For the time being, the studies dis­
cussed certainly cannot provide the answer to whether a 
local tissue renin-angiotensin system rather than the 
components circulating in plasma are the main determi­
nant of blood pressure homeostasis. The results pre­
sented do however demonstrate how much more can 
still be learned by measuring the octapeptide angioten­
sin II in plasma. The prospect, that tissue rather than 
plasma angiotensin II may determine vascular tone is 
certainly of great interest. However, much more work 
will have to be done before this hypothesis can be con­
firmed or refuted. 
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